In an industry where non-compliance can result in warning letters, product recalls, or delayed market access, compliance culture isn’t just a nice-to-have; it’s a strategic necessity. Regulators don’t just evaluate paperwork; they assess whether your teams understand and adhere to the processes behind that documentation.
But real-world compliance doesn’t happen in a vacuum. It depends on people. Employees across departments, from R&D and labeling to quality, packaging, and manufacturing, must all understand their role in compliance and take ownership of it. That’s where culture comes in.
This article explores how to build a culture of compliance through training, cross-functional alignment, communication, and smart integration of compliance processes like CER writing, regulatory CMC, and pharma regulatory submissions into daily workflows.
Many organizations rely heavily on regulatory or quality assurance (QA) teams to “own” compliance. While these departments are central, relying on a small group to maintain compliance across an entire pharmaceutical enterprise is unsustainable and risky.
Regulatory bodies like the FDA and EMA increasingly evaluate not only your data but also your culture. They want assurance that compliance is embedded at every level, not just during audits or inspections.
A true culture of compliance:
People are more likely to follow procedures when they understand the reason behind them. Employees need to know how their tasks contribute to:
Practical Tip: Host quarterly town halls where regulatory leads explain recent changes in guidelines, what’s coming next, and how it affects team responsibilities, especially for pharma regulatory submissions or updated regulatory CMC requirements.
Standard Operating Procedures are critical—but often misunderstood or misused. Employees may skim them, treat them as checklists, or skip sections they don’t see as relevant.
Training should evolve from “read and sign” to active engagement. For example, CER writing training for R&D teams should show how their clinical data is used and how errors can impact approval timelines.
A robust compliance culture thrives when each department sees regulatory quality as their responsibility, not just a function owned by QA.
Key cross-functional players include:
Strategy: Use cross-department compliance task forces to review internal audit results and drive remediation actions. These teams help shift ownership from reactive QA to proactive, organization-wide compliance.
Embedding regulatory adherence into routine activities is far more effective than treating it as an occasional obligation.
Suggestions:
By integrating compliance into business operations, you reduce the need for periodic compliance “sprints” before inspections.
One of the biggest threats to compliance? Silence. When employees don’t report issues – or worse, feel afraid to – small errors become big problems.
How to promote transparency:
Pharma CMC and CER writing teams should especially be encouraged to flag inconsistencies, outdated templates, or unclear data ownership, which often lead to compliance gaps in submissions.
Leadership support isn’t just about messaging; it’s about behavior. Senior leaders must prioritize compliance through their actions, resource allocation, and time.
Executive behaviors that foster compliance culture:
When leadership models regulatory adherence, employees follow.
As with any cultural initiative, continuous improvement matters. What gets measured gets managed.
Metrics to track include:
Use these insights to fine-tune your engagement strategy over time.
If compliance is framed as a burden, employees will treat it that way. But when it’s positioned as a shared mission tied to product quality, patient health, and professional excellence, it becomes a point of pride.
By making compliance personal, participatory, and performance-driven, your organization builds the kind of culture regulators respect and competitors envy.
NPG’s team of experts shares in our clients’ mission of creating a culture of compliance. Contact us today to start building your organization’s compliance culture.
When employees understand their impact on compliance, they’re more likely to provide accurate, timely data for pharma regulatory submissions, reducing errors and avoiding delays in approval timelines.
The regulatory CMC section requires inputs from manufacturing, quality, packaging, and labeling. Without collaboration, inconsistencies and data gaps can compromise the quality of the submission.
CER writing (Clinical Evaluation Reports) often draws from multiple teams. A culture of compliance ensures that teams provide accurate, validated data, supporting a well-documented, inspection-ready CER.
A weak compliance culture can lead to repeated audit findings, warning letters, internal confusion, high turnover in regulatory teams, and even product market withdrawal.
By championing compliance, allocating resources, reviewing metrics, and celebrating wins, leaders reinforce expectations without managing every detail. Their role is to empower, not police.
Ritu is an accomplished regulatory affairs professional with over 18 years of experience in the life sciences industry, including medical devices, pharmaceuticals, and biotech. As the President of Regulatory Affairs at Network Partners Group, Ritu has led the company through critical projects and business growth. With a Master’s degree in Regulatory Affairs from Northeastern University and a Bachelor’s degree in Honour Microbiology from the University of Guelph, Ritu has a proven track record in regulatory strategy, submissions, and agency interactions across the US, EU, and Canada.
"*" indicates required fields
